Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...
In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs ...
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results